Efficacy of Individualized Homeopathic Medicines in the Treatment of Sciatica Pain: Double-Blind, Randomized, Placebo-Controlled Trial.
Siddharth Kumar DasTrishita BasuSaleema Naaz TabassumAshish SarkarShubhamoy GhoshMunmun KoleySubhranil SahaArunava NathSrimanta KhamruiPublished in: Journal of integrative and complementary medicine (2024)
Objectives: Sciatica is a debilitating condition that causes pain in its distribution or in the lumbosacral nerve root that is connected to it. Although there are claims that homeopathy can reduce sciatica pain, systematic scientific proof is currently lacking. The objective of the trial was to determine whether individualized homeopathic medicines (IHMs) were as effective as identical-looking placebos in treating sciatica pain. Design: This is a double-blind, randomized (1:1), two parallel arms, placebo-controlled trial. Setting: The study was conducted at Mahesh Bhattacharyya Homoeopathic Medical College and Hospital, Howrah, West Bengal, India. Subjects: Sixty participants with sciatica pain were included in this study. Interventions: Verum ( n = 30; IHMs plus concomitant care) versus control ( n = 30; placebos plus concomitant care). Outcome measures: Primary-Sciatica Bothersome Index (SBI) and Sciatica Frequency Index (SFI) scores and secondary-Roland Morris Pain and Disability Questionnaire (RMPDQ), Short Form McGill Pain Questionnaire (SF-MPQ), and Oswestry Low Back Pain Questionnaire (OLBPQ) scores: all of them were measured at baseline, and every month, up to 3 months. Results: Intention-to-treat sample ( n = 60) was analyzed. Group differences were examined by two-way (split-half) repeated measure analysis of variance, primarily accounting for between groups and time interactions, and additionally, by unpaired t tests comparing the estimates obtained individually every month. The level of significance was set at p < 0.025 and <0.05 two tailed for the primary and secondary outcomes, respectively. Group differences could not achieve significance in SBI ( p = 0.044), SFI ( p = 0.080), and RMPDQ scores ( p = 0.134), but were significant for SF-MPQ ( p = 0.007) and OLBPQ ( p = 0.036). Gnaphalium polycephalum ( n = 6; 10%) was the most frequently prescribed medicine. No harm, serious adverse events, or intercurrent illnesses were recorded in either of the groups. Conclusions: The primary outcome failed to demonstrate evidently that homeopathy was effective beyond placebo, and the trial remained inconclusive. Independent replications are warranted to confirm the findings. Clinical Trial Registration Number: CTRI/2020/10/028617.
Keyphrases
- double blind
- chronic pain
- pain management
- clinical trial
- phase iii
- placebo controlled
- neuropathic pain
- phase ii
- healthcare
- study protocol
- open label
- randomized controlled trial
- adipose tissue
- multiple sclerosis
- spinal cord
- metabolic syndrome
- insulin resistance
- spinal cord injury
- type diabetes
- skeletal muscle
- weight loss
- cross sectional
- quality improvement
- adverse drug
- smoking cessation